Trial Profile
A Randomised, Partially Double Blind, Placebo and Positive Controlled, 4 Way Crossover Study to Evaluate the Effect of Icosabutate (NST 4016) on the QT/QTc Interval in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2019
Price :
$35
*
At a glance
- Drugs Icosabutate (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia; Hypertriglyceridaemia
- Focus Adverse reactions
- Sponsors NorthSea Therapeutics
- 24 Jan 2019 Status changed from recruiting to completed.
- 12 Jul 2018 New trial record